A message from our laboratories to yours: during these times of economic and personal hardship, we want to extend our sincerest support and hope you are keeping well.
Our response to COVID-19: Our laboratories remain open and committed to providing research services with a team continually monitoring the safety of our employees and business.
What are we doing to support research towards COVID-19 therapeutics? Check it out!
- We are providing multiplex testing for samples from COVID-19 patients in Phase 1 and Phase 2 clinical studies.
- Our multiplex testing is to monitor the cytokine storm and the effect of the experimental therapies on improving the patient condition.
- We are validating serological tests for immune status of patients with regards to COVID-19. The tests will indicate current or past infections. This assay will be available in the next 10-14 days.
From our products division, we offer immunology research products for the immunology and respiratory sectors. Also, we are currently collaborating with other laboratories on vaccines, developing drugs for COVID-19 that require our antibodies or assay products to be used in in-vitro studies.
In addition to work dedicated to the COVID-19 pandemic, we are still providing our in-house research services from preclinical to clinical studies across a wide range of therapeutic areas. Check out a few service areas below to learn more:
Join us for a live Zoom presentation to gain a better understanding about why we use pig models to advance translational pain research.